Leflunomide Aventis Pharma

Current Opinion in Investigational Drugs

Volumn 2, Issue 2, 2001, Pages 222-230

  Kaplan, M J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; COLESTYRAMINE; CORTICOSTEROID; CYCLOOXYGENASE 2; CYCLOSPORIN A; CYTOCHROME P450 2C9; DIHYDROOROTATE DEHYDROGENASE; GOLD SALT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN RADICAL; PLACEBO; PROTEIN TYROSINE KINASE; PYRIMIDINE; RIFAMPICIN; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG CARCINOGENICITY; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SYNTHESIS; EXPERIMENTAL MODEL; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HUMAN; HYPERTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MULTIPLE SCLEROSIS; NONHUMAN; PANCYTOPENIA; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; TERATOGENICITY;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; ISOXAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035110698     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent
2. Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide
3. 3-Carboxy-5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide, a new prodrug for the antiarthritic agent 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide
4. Therapeutic effects of leflunomide, a new antirheumatic drug, on glomerulonephritis induced by the antibasement membrane antibody in rats
5. Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats
6. Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis
7. Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats
8. Development of autoimmunity in MRL/Ipr mice and the effects of drugs on this murine disease
9. The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery
10. Hoechst's leflunomide licensed to Kyorin
11. Leflunomide, a novel immunosuppressive agent: The mechanism of inhibition of T cell proliferation
12. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine
13. B cell suppressor touted as transplant drug
14. Measurement of the active leflunomide metabolite (A771726) by reverse-phase high-performance liquid chromatography
15. Immunomodulatory activity of leflunomide on acute and chronic relapsing experimental allergic encephalomyelitis
16. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide
17. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase
18. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide
19. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study
20. Efficacy of leflunomide to reduce xenoantibody titers in vivo: An evaluation of the prolongation of discordant xenografts survival
21. HMR sets development priorities
22. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis
23. Leflunomide inhibits homotypic adhesion of mononuclear cells and granulocytes in RA
24. The anti-inflammatory drug leflunomide inhibits in vitro and in vivo the activity of COX-2 more potently than the induction of COX-2 or iNOS
25. Lefunomide induces apoptosis of leukocytes and T cell hybridomas
26. A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug
27. HMR filing arthritis drug in EC & US
28. Arava/Methotrexate combo may expand indication to refractory patients
29. Hoechst Arava pregnancy registry recommended to track teratogenicity
30. Hoechst Marion Roussel's Arava approved by FDA for treatment of adult rheumatoid arthritis (RA): First new disease-modifying agent developed specifically for RA in more than a decade
31. FDA advisory committee meetings
32. New study showed Arava (leflunomide) effectively reduced symptoms of rheumatoid arthritis (RA)
33. New study shows Arava (leflunomide) slowed progression of rheumatoid arthritis and improved physical function data supports use of new disease-modifying drug in adults with active rheumatoid arthritis
34. American College of Rheumatology - 62nd National Meeting, San Diego, CA, USA
35. Drug development pipeline: Leflunomide
36. The primary mode of action of leflunomide in rheumatoid arthritis is inhibition of de novo pyrimidine synthesis
37. Arava receives positive opinion from European CPMP for treatment of rheumatoid arthritis Frankfurt, Germany
38. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-bind, randomised, multicentre trial. European Leflunomide Study Group
39. Hoechst Marion Roussel Amaryl sales reach $62 million in second quarter
40. Arava receives approval for treatment of rheumatoid arthritis in Europe
41. Aventis, new world leader in life sciences, launched today; Rhône-Poulenc shareholders overwhelmingly approve final steps of merger with Hoechst; Supervisory Board members appointed; full listing on world stock exchanges on December 20
42. Advances in anti-arthritic agents, London, UK
43. Methotrexate, leflunomide effective for RA, US trial results
44. Lehman Brothers: A guide to product submissions and approvals in 2000
45. New drugs for the treatment of rheumatoid arthritis
46. Aventis Pharma - New data indicate Arava significantly improves long-term functional ability in rheumatoid arthritis - Additional data presented this week suggest Arava improves function as early as four weeks in rheumatoid arthritis patients
47. Drug development pipeline: Arava
48. Leflunomide: An immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases
49. Mechanisms of action of new immunosuppressive drugs
50. Leflunomide inhibits proliferation of TH1 effectors and biases for TH2 cell differentiation
51. Increased bone resorption in patients with active rheumatoid arthritis normalizes during treatment with leflunomide
52. Diabetic rats transplanted with adult porcine islets and immunosuppressed with cyclosporine, mycophenolate mofetil, and leflunomide remain normoglycemic for up to 100 days
53. Arava™ leflunomide
54. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis
55. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis
56. Early and sustained improvement of functional ability in active rheumatoid arthritis with leflunomide
57. The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone: A double-blind placebo controlled study
58. Efficacy of leflunomide vs. placebo vs. methotrexate in early and late rheumatoid arthritis
59. Onset of effect and duration of response to leflunomide treatment of active rheumatoid arthritis (RA) compared to placebo or methotrexate
60. Leflunomide efficacy in RA compared with some other DMARDS: Gold salts, methotrexate and cyclosporin
61. One year community-based experience with leflunomide in the treatment of rheumatoid arthritis
62. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group
63. A pilot study of leflunomide in systemic lupus erythematosus
64. Maintenance of remission with leflunomide in 11 patients with Wegener's granulomatosis
65. Mechanism of action of leflunomide in rheumatoid arthritis
66. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy and lactation
67. Adverse effects of leflunomide treatment in patients with rheumatoid arthritis
68. Severe pancytopenia after leflunomide in rheumatoid arthritis
69. Leflunomide approved for rheumatoid arthritis; Other drugs nearing approval (news)
70. What is the best source of useful data on the treatment of rheumatoid arthritis: Clinical trials, clinical observations or clinical protocols?
71. Treatment of rheumatoid arthritis
72. Musculoskeletal syndromes in malignancy
73. Leflunomide investigator's brochure
74. Rheumatoid arthritis. Epidemiology, pathology and pathogenesis
75. Treatment of rheumatoid arthritis